Indication
Central Nervous System Metastases
3 clinical trials
5 products
Clinical trial
A Multicenter Phase 2/3 Trial of the Efficacy and Safety of Intracerebroventricular Radioimmunotherapy Using 131I-omburtamab for Neuroblastoma Central Nervous System/Leptomeningeal MetastasesStatus: Terminated, Estimated PCD: 2023-06-02
Product
131I-omburtamabClinical trial
Efficacy and Safety of Furmonertinib for Epidermal Growth Factor Receptor (EGFR) Sensitive Mutation Positive Non-Small Cell Lung Cancer (NSCLC) Patients With Brain Metastasis: a Prospective Observational StudyStatus: Recruiting, Estimated PCD: 2024-09-30
Product
FurmonertinibClinical trial
A Phase II Study of Atezolizumab in Combination With Pertuzumab Plus High-dose Trastuzumab for the Treatment of Central Nervous System Metastases in Patients With Her2-positive Breast CancerStatus: Active (not recruiting), Estimated PCD: 2020-05-20
Product
ATEZOLIZUMABProduct
PERTUZUMABProduct
TRASTUZUMAB